New drug to stop tuberculosis epidemic

Researchers at the University of Manchester are developing a new drug against tuberculosis (TB), one of the oldest human infectious diseases, which is now threatening to reach epidemic proportions once more.

TB poses a serious threat to all nations with its incidence and mortality continuing to grow worldwide, triggered by new viral infections like HIV. It has coexisted with the human population since the Iron Age and currently infects one third of the population.

About 90% of infected people carry a latent infection for a lifetime span; the remainder develop the active disease triggered by age, poor health and poverty, as well as by co-infections. Despite the decline of the disease thanks to the introduction of vaccines in the last century, the emergence of new viral infections like HIV/AIDS has resulted in resurgence of TB. Today, more people die of TB than of any other curable infectious disease. TB has turned into a health threat of serious proportions with a major social and economic impact all around the world.

In addition the disease's long history and the problematic use of previous treatments have resulted in the multi-drug resistant strains.

Dr Lydia Tabernero and her team, together with Dr Jen Cavet at the Faculty of Life Sciences, have been awarded £700,000 Medical Research Council (MRC) funding to develop a drug against the disease that will be simpler to use, quicker in its action and, being new, able to combat even drug resistant strains. This research will be developed in collaboration with Professor Franzblau and Dr Abad-Zapatero at the University of Illinois in Chicago.

Dr Tabernero explains: “Antibiotic resistance is the most serious obstacle in the cure and eradication of TB. This is, in part, due to lack of compliance from patients during the complex and long treatment. Multi-drug resistant TB now affects more than 50 million people, with an increasing percentage of cases evolving into extensively drug resistant TB that is extremely hard to treat.

“Existing treatments are more than 40 years old. Clearly, to tackle drug resistance and prevent future epidemics, we need new approaches and novel anti-TB drugs. Several promising compounds are now under development with a few in clinical trials, while alternative potential targets are also being characterised.

“New approaches and therapeutical treatments are urgently needed to tackle the increasing spread of the infection, by reducing drug resistance, time of treatment and to be compatible with anti-retroviral therapies. We propose to fulfil these unmet therapeutical needs by targeting a unique virulence factor (MptpB) from the causing agent of TB, M. tuberculosis.”

Dr Tabernero added: “We are very pleased to have received this funding as it will allow us to develop a drug that will combat a dangerous but somewhat overlooked disease.

“A main bottleneck in the development of inhibitory compounds is that generally resources and expertise are concentrated in the private sector. Companies are highly reluctant to allocate serious investments in ‘poor people's diseases’ that would compromise their return benefits.

“We have characterised the activity profile of a protein known to be a virulence factor for TB causing bacteria and propose to develop a new drug against this target to treat TB. We have already identified compounds, which are potent inhibitors of this protein. To take our ambitions further, we must now develop some of the leads we have identified and be able to test them. This will only be possible in a non-profit academic environment at this stage.”

Dr Tabernero hopes to develop the new drug within three to four years and to start clinical trials in the near future.

Source: University of Manchester

Related stories:

FDA orders stronger warnings for 4 arthritis drugs
(AP) -- The Food and Drug Administration ordered stronger warnings Thursday on four medications widely used to treat rheumatoid arthritis and other serious illnesses, saying they can raise the risk of possibly fatal fungal infections.
Researchers offer first direct proof of how osteoarthritis destroys cartilage
A team of orthopaedic researchers has found definitive, genetic proof of how the most common form of arthritis destroys joint cartilage in nearly 21 million aging Americans, according to a study published online Sept. 2 in the Journal of Bone and Mineral Research. The findings serve as an important foundation for the design of new treatments for osteoarthritis (OA), researchers said.
Millions face undiagnosed heart risk say researchers after mass screening
One in three people with a high risk of developing cardiovascular disease (CVD) over the next 10 years have not been diagnosed, according to a major UK study in the September issue of IJCP, the International Journal of Clinical Practice.
Family therapy helps relieve depression symptoms in bipolar teens
Family-focused therapy, when combined with medication, appears effective in stabilizing symptoms of depression among teens with bipolar disorder, according to a report in the September issue of Archives of General Psychiatry.
New genes found for inflammatory bowel disease in children
Researchers have discovered two new genes that increase the risk of developing inflammatory bowel disease (IBD) in childhood.
Scientists discover new link in pathway to cancer: hope for drug design
(PhysOrg.com) -- University of Manchester scientists have identified an exciting connection between a cell’s extracellular environment and the activity of a signalling pathway molecule that controls the development of organs and tissues, as well as cancer and kidney disease.
CDC: Salmonella outbreak appears to be over
(AP) -- The government said Thursday that the salmonella outbreak that sickened at least 1,440 people appears to be over, but its ultimate source may never be known, partly because of shortcomings in the nation's food safety system.
Class of diabetes drugs carries significant cardiovascular risks
A class of oral drugs used to treat type 2 diabetes may make heart failure worse, according to an editorial published online in Heart Wednesday by two Wake Forest University School of Medicine faculty members.

News discussion:

Medicine & Health news